Celluvisc 0.5%
- Name:
Celluvisc 0.5%
- Company:
Allergan Ltd
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 04/03/20

XPIL
Package leaflet: Information for the user
Package leaflet: Information for the user
1. What CELLUVISC® is and what it is used for
1. What CELLUVISC® is and what it is used for
2. What you need to know before you use CELLUVISC®
2. What you need to know before you use CELLUVISC®
3. How to use CELLUVISC®
3. How to use CELLUVISC®
4. Possible side effects
4. Possible side effects
5. How to store CELLUVISC®
5. How to store CELLUVISC®
6. Contents of the pack and other information
6. Contents of the pack and other information

Print ViewKeyword Search SPC
1. NAME OF THE MEDICINAL PRODUCT
1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4. CLINICAL PARTICULARS
5. PHARMACOLOGICAL PROPERTIES
5. PHARMACOLOGICAL PROPERTIES
6. PHARMACEUTICAL PARTICULARS
6. PHARMACEUTICAL PARTICULARS
7. MARKETING AUTHORISATION HOLDER
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
10. DATE OF REVISION OF THE TEXT
Allergan Ltd

Company Products
Medicine Name | Active Ingredients |
---|---|
Medicine Name Acular | Active Ingredients Ketorolac Trometamol |
Medicine Name Alphagan | Active Ingredients brimonidine tartrate |
Medicine Name Betagan Unit Dose | Active Ingredients Levobunolol hydrochloride |
Medicine Name BOTOX 100 Units | Active Ingredients Botulinum Toxin Type A |
Medicine Name BOTOX 200 Units | Active Ingredients Botulinum Toxin Type A |
Medicine Name BOTOX 50 Units | Active Ingredients Botulinum Toxin Type A |
Medicine Name Celluvisc 0.5% | Active Ingredients Carmellose sodium |
Medicine Name Celluvisc 1.0% w/v Eye drops, solution | Active Ingredients Carmellose sodium |
Medicine Name Combigan | Active Ingredients brimonidine tartrate, Timolol Maleate |
Medicine Name Exocin | Active Ingredients Ofloxacin |
Medicine Name FML | Active Ingredients Fluorometholone |
Medicine Name Ganfort | Active Ingredients Bimatoprost, Timolol Maleate |
Medicine Name Ganfort SD | Active Ingredients Bimatoprost, Timolol Maleate |
Medicine Name Lacri-Lube | Active Ingredients No Active Ingredients |
Medicine Name Liquifilm Tears | Active Ingredients Polyvinyl Alcohol |
Medicine Name Lumigan 0.1mg/ml | Active Ingredients Bimatoprost |
Medicine Name Ozurdex | Active Ingredients Dexamethasone |
Medicine Name Pred Forte | Active Ingredients Prednisolone Acetate |
Medicine Name Pred Mild | Active Ingredients Prednisolone Acetate |
Medicine Name Refresh Ophthalmic | Active Ingredients Polyvinyl Alcohol, Povidone |
Medicine Name Relestat 0.5 mg/ml, eye drops, solution | Active Ingredients Epinastine Hydrochloride |
Medicine Name Vistabel | Active Ingredients Botulinum Toxin Type A |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 4 March 2020 PIL
Reasons for updating
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 16 February 2015 SPC
Reasons for updating
- New SPC for new product
Legal category: Supply through pharmacy only
Updated on 16 February 2015 SPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 12 February 2015 PIL
Reasons for updating
- New PIL for new product
Updated on 12 February 2015 PIL
Reasons for updating
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 4 June 2014 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 30 May 2014 PIL
Reasons for updating
- Changes to therapeutic indications
- Change to storage instructions
- Change to side-effects
- Change to information about driving or using machinery
- Change to date of revision
Updated on 10 March 2011 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Summary of Changes to Celluvisc® 0.5% Irish Summary of Product Characteristics (SPC)
The current Celluvisc® SPC is dated 17th December 2010
This supersedes SPC dated 10th November 2006
Section Number |
Subject |
Change |
4.8 |
Undesirable effects |
Added Text: The frequency of adverse reactions documented during clinical trials is given. The frequency is defined as follows: Very Common (³ 1/10); Common (³1/100, <1/10); Uncommon (³1/1,000, <1/100); Rare (³1/10,000, <1/1,000); Very Rare (<1/10,000), not known (cannot be estimated from the available data).
Eye disorders:
Common: Eye Irritation
The following other adverse reactions have reported since Cellufluid has been marketed: Eye pain, vision blurred, lacrimation increased, ocular hyperaemia.
Deleted Text:
|
10 |
Date of Revision of Text |
Text added:
|
Key:
Unchanged text appears as follows: eg sodium hydroxide
Added text appears as follows: eg Celluvisc
Deleted text appears as follows: eg Not applicable
Updated on 9 March 2011 PIL
Reasons for updating
- Change to side-effects
- Change to further information section
Updated on 21 February 2011 PIL
Reasons for updating
- Change to improve clarity and readability
Updated on 24 November 2006 PIL
Reasons for updating
- New PIL for new product
Updated on 24 November 2006 SPC
Reasons for updating
- New SPC for new product
Legal category: Supply through pharmacy only